FrancophonIA/ELRC3.0 huggingface dataset:
English: However the published data presented demonstrated the safety and efficacy of high-dose ciprofloxacin (daily dose of 1200 mg IV [or 1500 mg peroral]) with or without an option to oral switch, in various serious and life threatening infections.
Bulgarian: Framlagda publicerade data visade emellertid säkerhet och effekt hos ciprofloxacin i hög dos (daglig dos på 1 200 mg intravenöst [eller 1 500 mg peroralt]) med eller utan övergång till oral behandling som alternativ, vid olika allvarliga och livshotande infektioner. De sjukdomstillstånd som undersökts var svår lunginflammation, neutropeni, akuta bakteriella exacerbationer av kronisk bronkit, komplicerade samhällsförvärvade ytliga och djupare hudinfektioner, infektioner hos cancerpatienter och bakteriemi.
English: ≤1 µg/ml for susceptible, >1 µg/ml for resistant; - S. pneumonia ≤0.125 µg/ml for susceptible, >2 µg/ml for resistant; - Staphylococcus spp.
Bulgarian: µg/ml för resistenta; - S. pneumonia ≤ 0,125 µg/ml för känsliga, > 2 µg/ml för resistenta; - Staphylococcus spp. ≤ 1 µg/ml för känsliga, > 1 µg/ml för resistenta; - H. influenza och M.
English: Ear and inner ear disorders Rare:
Bulgarian: Öron och balansorgan Sällsynta:
English: increased blood sugar level (hyperglycaemia) Mental (psychiatric) disorders Rare:
Bulgarian: förhöjd blodsockernivå (hyperglykemi)
English: Rare: myalgia (muscular pain), joint disorder (swollen joints).
Bulgarian: Sällsynta: myalgi (muskelsmärta), ledstörning (svullna leder).
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of solution for infusion contains 2 mg ciprofloxacin (as hydrogen sulphate) [Each bag with 50 ml contains 100 mg ciprofloxacin.
Bulgarian: KVALITATIV OCH KVANTITATIV SAMMANSÄTTNING Varje ml injektionsvätska, lösning innehåller 2 mg ciprofloxacin (som vätesulfat).
English: Keep infusion bag in the overpouch until ready to use in order to protect from light.
Bulgarian: Förvara infusionspåsen i ytterpåsen tills den
English: Uncommon: increase in eosinophilic cells (eosinophilia), reduction in white blood cells (leucopenia)
Bulgarian: ökning av eosinofila celler (eosinofili), minskning av vita blodkroppar (leukopeni) vilket ökar risken för infektioner
English: Disorders of the kidney and urinary tract Rare:
Bulgarian: Njurar och urinvägar Sällsynta:
English: Fresenius Kabi Deutschland GmbH,D-61346 Bad Homburg v.d.H.,Germany Tel-No.: 0049 6172 686 0 Fax.No.
Bulgarian: Fresenius Kabi Deutschland GmbH,D-61346 Bad Homburg v.d.H.,TysklandTel-No.:
English: MARKETING AUTHORISATION HOLDER [See Annex I - To be completed nationally]
Bulgarian: INNEHAVARE AV GODKÄNNANDE FÖR FÖRSÄLJNING [Se Annex 1 - Kompletteras nationellt]
English: • bone infections.
Bulgarian: Infektioner och infestationer
English: PHARMACEUTICAL FORM AND CONTENTS Solution for infusion
Bulgarian: LÄKEMEDELSFORM OCH FÖRPACKNINGSSTORLEK Infusionsvätska, lösning.
English: As a result of its mechanism of action, ciprofloxacin does not show cross-resistance with other important, chemically different groups of substances such as beta-lactam antibiotics, aminoglycosides, tetracyclines, macrolides and polypeptides, sulphonamides, trimethoprim and nitrofurantoine.
Bulgarian: aminoglykosider, tetracykliner, makrolider och polypeptider, sulfonamider, trimetoprim och nitrofurantoin.
English: No data was presented comparing the efficacy, safety or prevention of bacterial resistance using the 800mg maximum IV dose licensed in the UK and the 1200mg IV ciprofloxacin proposed by the applicant.
Bulgarian: i Storbritannien godkända maximala intravenösa dosen om 800 mg med 1 200 mg ciprofloxacin intravenöst som den sökande har föreslagit.
English: Pseudomonas aeruginosa
Bulgarian: Pseudomonas aeruginosa - till patienter
English: anxieties, nightmares, severe depression, seeing things or hearing voices that do not exist (hallucinations)
Bulgarian: oro, mardrömmar, allvarlig depression, syner och ljudupplevelser
English: • children and growing adolescents except for the treatment of acute lower respiratory tract infections caused by Pseudomonas aeruginosa bacteria in children and adolescents aged 5-17 years with cystic fibrosis
Bulgarian: - till barn och växande ungdomar förutom barn och ungdomar mellan 5 och 17 år som har cystisk fibros och som behandlas för akuta infektioner i de nedre luftvägarna orsakad av bakterien
English: • Store the infusion bag in the overpouch until it is used in order to protect from light.
Bulgarian: - Förvara infusionspåsen i ytterpåsen tills den
English: Since the risks for humans are unknown Ciprofloxacin Kabi must not be administered during pregnancy (see section 4.3).
Bulgarian: Hos juvenila och prenatala djur som exponerats för kinoloner har effekter på omoget brosk observerats. Eftersom riskerna för människa inte är kända får Ciprofloxacin Kabi ej ges under graviditet (se avsnitt 4.3).
English: The bioavailability of ciprofloxacin after oral administration is between 70 % and 85 %.
Bulgarian: samband mellan dos och plasmakoncentration samt mellan dos och AUC. Biotillgängligheten av ciprofloxacin efter peroral administrering är mellan 70 % - 85 %.
English: Characteristics in patients:
Bulgarian: Patientkarakteristika
English: Klebsiella oxytoca
Bulgarian: coli ESBL producerande Klebsiella pneumoniae Klebsiella oxytoca
English: Signs of these reactions are: a sharp drop in blood pressure, paleness, restlessness, weak/rapid pulse, clammy skin, dizziness.
Bulgarian: Symtom på sådana reaktioner är: kraftigt minskat blodtryck, blekhet, rastlöshet, svag/snabb puls, fuktig eller klibbig hud och yrsel. I mycket sällsynta fall kan dessa överkänslighetsreaktioner leda till livshotande chock.
English: Uncommon: pruritis, papillo-macular rash, urticaria.
Bulgarian: Mindre vanliga: prurit, papillomakulära utslag, urtikaria.
English: The applicant/MAH performed a review of published clinical studies from the mid 1990's to date, to support the recommended posology of 200-400 mg ciprofloxacin twice daily in the treatment of complicated urinary tract infections.
Bulgarian: igenom publicerade kliniska studier från mitten av 1990-talet fram till idag, till stöd för den rekommenderade doseringen 200-400 mg ciprofloxacin två gånger dagligen vid behandling av komplicerade urinvägsinfektioner. I majoriteten av studierna användes en behandling med 500 mg två gånger dagligen per os (via munnen).
English: • The other ingredients are sodium chloride, sulphuric acid, sodium hydroxide for pH adjustment, water for injections
Bulgarian: FÖRTECKNING ÖVER HJÄLPÄMNEN Natriumklorid, svavelsyra, natriumhydroxid, vatten för injektionsvätskor
English: • known allergic reaction to ciprofloxacin or any of the other ingredients of Ciprofloxacin Kabi or other medicines of the quinolone type
Bulgarian: Ciprofloxacin Fresenius Kabi eller mot andra mediciner av kinolontyp
English: In this leaflet:
Bulgarian: som kännetecknas av:
English: • myastenia gravis (a particular type of muscle weakness).
Bulgarian: - myasthenia gravis (en sjukdom
English: NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER [See Annex I - To be completed nationally]
Bulgarian: INNEHAVARE AV GODKÄNNANDE FÖR FÖRSÄLJNING (NAMN OCH ADRESS) [Se Annex 1 - Kompletteras nationellt]
English: Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin potentially leading to increased plasma levels of methotrexate.
Bulgarian: Renal tubulär transport av metotrexat kan hämmas vid samtidig administrering av ciprofloxacin.
English: rash
Bulgarian: Batch
English: Like with other gyrase inhibitors, ciprofloxacin may induce joint damage during the growth phase of juvenile animals.
Bulgarian: I likhet med andra gyrashämmare kan ciprofloxacin inducera ledskador under
English: Uncommon: vomiting, dyspepsia, flatulence, anorexia, abdominal pain.
Bulgarian: Mindre vanliga: kräkningar, dyspepsi, flatulens, aptitlöshet, magsmärtor.
English: The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections.
Bulgarian: Därför är det viktigt att få information om lokala resistensmönster, särskilt vid behandling av svårare infektioner.
English: Each bag with 100 ml contains 200 mg ciprofloxacin.
Bulgarian: Varje påse med 100 ml innehåller 200 mg ciprofloxacin.
English: Hypersensitivity:
Bulgarian: - ökad känslig mot
English: In patients on haemodialysis or CAPD, the maximum daily intravenous dose is also 400 mg. On the dialysis days, the dose is given after the haemodialysis session.
Bulgarian: som får hemodialys eller CAPD är den maximala intravenösa dagsdosen 400 mg.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each ml of solution for infusion contains 2 mg ciprofloxacin (as hydrogen sulphate) Each bag with 50 ml contains 100 mg ciprofloxacin.
Bulgarian: DEKLARATION AV AKTIV(A) SUBSTANS(ER) Varje ml injektionsvätska innehåller 2 mg ciprofloxacin (som vätesulfat).
English: Each bag of 200 ml contains 400 mg of ciprofloxacin.
Bulgarian: Varje påse med 200 ml innehåller 400 mg ciprofloxacin.
English: Twice daily intravenous administration of 15 mg/kg bodyweight, or 10 mg/kg bodyweight three times daily (maximum of 1200 mg per day).
Bulgarian: 15 mg/kg kroppsvikt via intravenös administrering två gånger dagligen eller 10 mg/kg kroppsvikt
English: Twelve hours after i.v.
Bulgarian: timmar efter peroralt
English: Each bag of 100 ml contains 200 mg of ciprofloxacin.
Bulgarian: Varje påse om 100 ml innehåller 200 mg ciprofloxacin.
English: Eye disorders Rare:
Bulgarian: Ögon Sällsynta:
English: HOW TO STORE CIPROFLOXACIN KABI
Bulgarian: Hur Ciprofloxacin Fresenius Kabi
English: Photosensibility:
Bulgarian: Överkänslighet
English: Acinetobacter baumannii
Bulgarian: Acinetobacter baumannii Campylobacter spp.
English: Method of administration
Bulgarian: Verkningsmekanism
English: You should consult your doctor if you are breast-feeding your child.
Bulgarian: Du skall rådfråga din läkare innan du använder Ciprofloxacin Fresenius Kabi om du ammar ditt barn.
English: HOW TO USE CIPROFLOXACIN KABI
Bulgarian: HUR DU ANVÄNDER CIPROFLOXACIN FRESENIUS KABI
English: General disorders and administration site conditions:
Bulgarian: Allmänna symtom och/eller symtom vid administreringsstället Mindre vanliga:
English: intravenous dose.
Bulgarian: - nedsatt leverfunktion.
English: B-2627 Schelle, Belgium Tel-No.: 0032 3 880 5024 Fax.No.
Bulgarian: 0032 3 880 5024 Fax.No.:
English: Musculoskeletal, conective tissue and bone disorders:
Bulgarian: Muskuloskeletala systemet och bindväv Mindre vanliga:
English: Infections and infestations Uncommon: fungal infection (moniliasis)
Bulgarian: svampinfektion (moniliasis)
English: Glibenclamide
Bulgarian: Svavelsyra
English: Achilles tendon) has been reported, especially in elderly patients who were previously treated systemically with glucocorticoids.
Bulgarian: som tidigare behandlats med systemiska glukokortikoider.
English: perspiration Investigations
Bulgarian: INFORMATION I BLINDSKRIFT
English: Nervous system disorders:
Bulgarian: centrala nervsystemet. Följande biverkningar har observerats:
English: The following adverse reactions have been observed:
Bulgarian: som listas nedan bör särskild hänsyn vidtas:
English: Ciprofloxacin Kabi 2 mg/ml, solution for infusion
Bulgarian: Ciprofloxacin Kabi 2 mg/ml, infusionsvätska, lösning
English: Most frequent adverse reactions involve the gastro-intestinal tract and the central nervous system.
Bulgarian: De vanligaste biverkningarna är gastrointestinala besvär och påverkan på det
English: • Keep this leaflet.
Bulgarian: Läs noga igenom denna bipacksedel
English: Common:
Bulgarian: Vanliga
English: Ciprofloxacin Kabi and associated names (See Annex I) 400 mg/200 ml solution for infusion [See Annex I - To be completed nationally]
Bulgarian: Ciprofloxacin Fresenius Kabi 2 mg/ml, infusionsvätska, lösning [Se Annex 1 - Kompletteras nationellt]
English: From a microbiological point of view, the product should be used immediately.
Bulgarian: Från mikrobiologisk synvinkel
English: Ciprofloxacin Fresenius Kabi 400 mg/200 ml,solution for infusion
Bulgarian: Ciprofloxacin Fresenius Kabi 400 mg/200 ml,infusionsvätska, lösning
English: Psychiatric disorders:
Bulgarian: Psykiska störningar Sällsynta:
English: ≤0.5 µg/ml for susceptible, >1 µg/ml for resistant; - Acinetobacter spp.
Bulgarian: - Enterobacteriaceae: ≤ 0,5 µg/ml för känsliga, > 1 µg/ml för resistenta; - Pseudomonas spp. ≤ 0,5 µg/ml för känsliga, > 1 µg/ml för resistenta; - Acinetobacter spp. ≤ 1 µg/ml för känsliga, > 1
English: Ciprofloxacin Fresenius Kabi 2 mg/ml, solution for infusion
Bulgarian: Ciprofloxacin Fresenius Kabi 2 mg/ml,
English: Maintaining fluoroquinolone class efficacy: review of influencing factors.
Bulgarian: Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis. 2003 Jan;9(1):1-9.
English: Ciprofloxacin Fresenius Kabi 200 mg/100 ml, solution for infusion
Bulgarian: Ciprofloxacin Fresenius Kabi 200 mg/100 ml, infusionsvätska, lösning
English: Ciprofloxacin inhibits CYP1A2 and thus may cause increased serum concentration of concomitantly administered substances metabolised by this enzyme (e.g. theophylline, clozapine, tacrine, ropinirol, tizanidine).
Bulgarian: Ciprofloxacin hämmar CYP1A2 och kan därmed orsaka ökad serumkoncentration av samtidigt givna substanser
English: Antiperistaltics are contraindicated.
Bulgarian: sättas ut och lämplig behandling påbörjas. Antiperistaltiska medel är kontraindicerade.
English: Ciprofloxacine Kabi 400 mg/200 ml, solution for infusion
Bulgarian: Ciprofloxacine Kabi 400 mg/200 ml, infusionsvätska, lösning
English: Applicant
Bulgarian: Sökanden
English: Ciprofloxacine Kabi 200 mg/100 ml, solution for infusion
Bulgarian: Ciprofloxacine Kabi 200 mg/100 ml, infusionsvätska, lösning
English: Ciprofloxacin Kabi 400 mg/200 ml, solution for infusion
Bulgarian: Ciprofloxacin Kabi 400 mg/200 ml, infusionsvätska, lösning
English: Uncommon: arthralgia (joint pain).
Bulgarian: Mindre vanliga: artralgi (ledsmärta).
English: Impaired renal and hepatic function:
Bulgarian: Nedsatt njur- och leverfunktion:
English: Route of administration
Bulgarian: Magtarmkanalen
English: Ciprofloxacin Kabi 200 mg/100 ml, solution for infusion
Bulgarian: Ciprofloxacin Kabi 200 mg/100 ml, infusionsvätska, lösning
English: If there is any indication of tendinitis (e.g. painful swelling) the administration of ciprofloxacin or other fluoroquinolones must immediately be discontinued, the affected extremity should not be strained and a physician must be consulted.
Bulgarian: skall administreringen av ciprofloxacin eller andra fluorokinoloner omedelbart avbrytas, den berörda armen/benet ej påfrestas och en läkare konsulteras. Partiell eller fullständig senruptur (framförallt av hälsenan) har rapporterats i mycket sällsynta fall, framförallt hos äldre patienter
English: increased sensitivity to light (photosensitivity)
Bulgarian: ökad ljuskänslighet
English: If you experience these symptoms you should immediately consult your doctor and rest the respective leg.
Bulgarian: så kallade steroidgruppen, såsom hydrokortison. Om du upplever dessa symtom bör du omedelbart kontakta läkare och undvika att belasta den drabbade senan.
English: Ciprofloxacine Kabi 100 mg/50 ml, solution for infusion
Bulgarian: Ciprofloxacine Kabi 100 mg/50 ml, infusionsvätska, lösning
English: • certain lower respiratory tract infections including pneumonia
Bulgarian: - komplicerade urinvägsinfektioner - vissa infektioner i de nedre luftvägarna inklusive lunginflammation - komplicerade infektioner i hud och mjukdelar - infektioner i ben (skelett)
English: Unless compatibility is proven, the solution for infusion should always be administered separately (see also section 6.2).
Bulgarian: Kompatibilitet med dessa lösningar har visats i spädningsområdet 1+1 och 1+4, motsvarande ciprofloxacinkoncentrationer på 0,4 till 1 mg/ml. Om kompatibilitet inte är dokumenterad skall infusionslösningen alltid ges separat (se även avsnitt 6.2).
English: Uncommon: (thrombo)phlebitis.
Bulgarian: (trombo)flebiter.
English: Ciprofloxacin Kabi 100 mg/50 ml, solution for infusion
Bulgarian: Ciprofloxacin Kabi 100 mg/50 ml,infusionsvätska, lösning
English: Ciprofloxacin Kabi 100 mg/50 ml,solution for infusion
Bulgarian: Ciprofloxacin Kabi 100 mg/50 ml, infusionsvätska, lösning
English: [Ciprofloxacin Kabi 100 mg/50 ml solution for infusion: pack sizes: 1, 5, 10, 20, 30 or 40 bags.
Bulgarian: förpackningsstorlekar 200 ml: 1, 5, 10, 20, 30 eller 40 påsar.
English: Take special care with Ciprofloxacin Kabi
Bulgarian: VAD CIPROFLOXACIN FRESENIUS KABI
English: Breast-feeding
Bulgarian: BIPACKSEDEL
English: p.o. was used.
Bulgarian: ÄR OCH VAD DET ANVÄNDS FÖR
English: SUMMARY OF PRODUCT CHARACTERISTICS
Bulgarian: För mer detaljer angående biverkningar
English: Ciprofloxacin exerts a rapid bactericidal effect by inhibiting DNA-gyrase, resulting in inhibition of DNA synthesis.
Bulgarian: som är effektiv in vitro mot ett stort antal gramnegativa aeroba bakterier liksom mot vissa grampositiva organismer. Ciprofloxacin har en snabb baktericid effekt genom att hämma DNA-gyras, vilket resulterar
English: You must NOT be given Ciprofloxacin Kabi in the following cases:
Bulgarian: till Ciprofloxacin Kabi och synonymer (se bilaga I), med beaktande av följande:
English: Rare: transpiration.
Bulgarian: Vanliga: hudutslag.
English: This was recorded in two questionnaires completed at home.
Bulgarian: Това се документира с два въпросника, попълвани у дома.
English: • patients who have had a stroke or a heart attack within the last six months;
Bulgarian: - пациенти, които са претърпели удар или инфаркт през последните шест месеца;
English: The full EPAR for Vivanza can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Bulgarian: Vivanza може да се намери на уебсайта на Агенцията: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: A risk management plan has been developed to ensure that Vivanza is used as safely as possible.
Bulgarian: Разработен е план за управление на риска, за да се гарантира, че Vivanza се използва възможно най-безопасно.
English: What measures are being taken to ensure the safe and effective use of Vivanza?
Bulgarian: Какви мерки се предприемат, за да се гарантира безопасната и ефективна употреба на Vivanza?
English: The main measure of effectiveness was the ability to get and maintain an erection.
Bulgarian: Основната мярка за ефективност е способността да се получи и задържи ерекция.
English: It must not be used when sexual activity is inadvisable, such as in men with severe heart disease.
Bulgarian: Не трябва да се прилага, когато сексуалната активност е непрепоръчителна, например при мъже с тежки сърдечни заболявания.
English: This is a summary of the European public assessment report (EPAR) for Vivanza.
Bulgarian: Настоящият документ представлява резюме на Европейския публичен оценъчен доклад (EPAR) за Vivanza.
English: Vivanza was significantly more effective than placebo for all measures in all studies.
Bulgarian: Vivanza е значително по-ефективен от плацебо по всички показатели във всички проучвания.
English: The CHMP decided that Vivanza's benefits are greater than its risks and recommended that it be given marketing authorisation.
Bulgarian: CHMP реши, че ползите от Vivanza са по-големи от рисковете, и препоръча да се издаде разрешение за употреба.
English: For more information about treatment with Vivanza, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Bulgarian: За повече информация относно лечението с Vivanza прочетете листовката (също част от EPAR) или попитайте Вашия лекар или фармацевт.
English: The dose may be increased to a maximum of 20 mg or decreased to 5 mg depending on the effectiveness and side effects.
Bulgarian: Дозата може да се увеличи до максимум 20 mg или да се намали до 5 mg в зависимост от ефективността и нежеланите лекарствени реакции.
English: Other information about Vivanza
Bulgarian: Допълнителна информация за Vivanza
English: Because Vivanza has not been studied in the following groups of patients, they must not use the medicine:
Bulgarian: Тъй като Vivanza не е проучен при тях, следните групи пациенти не трябва да го приемат:
English: Two additional main studies compared orodispersible tablets with placebo in 701 men aged 21 to 84 years.
Bulgarian: Две допълнителни основни проучвания сравняват таблетките, диспергиращи се в устата, с плацебо при 701 мъже на възраст от 21 до 84 години.
English: Patients with liver problems or severe kidney problems should start treatment on the 5 mg dose.
Bulgarian: Пациенти с чернодробни проблеми или тежки бъбречни проблеми трябва да започнат лечение с доза от 5 mg.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Vivanza, including the appropriate precautions to be followed by healthcare professionals and patients.
Bulgarian: Въз основа на този план информацията за безопасността е включена в кратката характеристика на продукта и в листовката за Vivanza, включително подходящи предпазни мерки за здравните специалисти и пациентите.
English: The recommended dose of Vivanza is 10 mg, taken by mouth with or without food, about 25 to 60 minutes before sexual activity; patients should not take more than one dose a day.
Bulgarian: Препоръчителната доза е 10 mg, приемана около 25 до 60 минути преди сексуална активност; пациентите не трябва да приемат повече от една доза на ден.
English: If Vivanza is taken with a high fat meal, the onset of activity may be delayed.
Bulgarian: Ако Vivanza се приема с храна с високо мастно съдържание, началото на действие може да се забави.
English: • patients who have hypotension (low blood pressure);
Bulgarian: - пациенти с хипотония (ниско кръвно налягане);
English: By blocking the breakdown of cGMP, Vivanza restores erectile function.
Bulgarian: Като блокира разграждането на cGMP, Vivanza възстановява еректилната функция.
English: It is available as film-coated tablets (5, 10 and 20 mg) and as orodispersible tablets (10 mg).
Bulgarian: Предлага се под формата на филмирани таблетки (5, 10 и 20 mg) и таблетки, диспергиращи се в устата (10 mg).
English: The most common side effect with Vivanza (seen in more than 1 patient in 10) is headache.
Bulgarian: Най-честата нежелана лекарствена реакция при Vivanza (наблюдавана при повече от 1 на 10 пациенти) е главоболие.
English: This allows blood to flow into the corpora, producing the erection.
Bulgarian: Това позволява приток на кръв в corporа и създава ерекция.
English: The dose may need to be adjusted in patients taking other medicines that block enzymes that break down Vivanza.
Bulgarian: Възможно е да се наложи коригиране на дозата при пациенти, приемащи други лекарства за инхибиране на ензимите, които разграждат Vivanza.
English: Vivanza is a medicine that contains the active substance vardenafil.
Bulgarian: Vivanza представлява лекарство, съдържащо активното вещество варденафил (vardenafil).
English: Vivanza film-coated tablets have been compared with placebo (a dummy treatment) in four main studies including 2,431 men aged 20 to 83 years.
Bulgarian: Vivanza филмирани таблетки е сравнен с плацебо (сляпо лечение) в четири основни проучвания при 2431 пациенти на възраст от 20 до 83 години.
English: For the full list of all side effects reported with Vivanza, see the package leaflet.
Bulgarian: За пълния списък на всички нежелани лекарствени реакции, съобщени при Vivanza, вижте листовката.
English: Vivanza is used to treat adult men with erectile dysfunction (sometimes called impotence), when they cannot get, or keep, a hard penis (erection) sufficient for satisfactory sexual activity.
Bulgarian: Vivanza се използва за лечение на възрастни мъже с еректилна дисфункция (понякога наричана импотентност), когато когато не могат да получат или задържат твърд пенис (ерекция), необходим за успешен полов акт.
English: The active ingredient of Vivanza, vardenafil, belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors.
Bulgarian: Активната съставка във Vivanza, варденафил, принадлежи към групата лекарства, наричани инхибитори на фосфодиестераза тип 5 (PDE5).